2018 Clinic Nuclear Medicine PET Scan 
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. The nuclear radiologist, nuclear medicine technologist, and radiation safety team are all present to administer an infusion.
AuntMinnie
DECEMBER 19, 2023
Clinical brain imaging with a newly developed portable PET scanner appears feasible, with a comparison to conventional PET imaging for the first time revealing similar results in human subjects, according to a group in New York City. The study was published on December 14 in the Journal of Nuclear Medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. The nuclear radiologist, nuclear medicine technologist, and radiation safety team are all present to administer an infusion.
Imaging Technology
MAY 31, 2023
Flavio Forrer , MD, PhD, Chairman of Nuclear Medicine in the Division of Radiology and Nuclear Medicine at Kantonsspital St. CR and CNR demonstrated using clinical data with inserted lesions of known size, location, and contrast. Measurement follows NEMA NU 2-2018. [v] Gallen in Switzerland [vii].
Imaging Technology
JUNE 15, 2023
The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Fruhwirth, G. Kneilling, M., De Vries, I. Weigelin, B.,
Expert insights. Personalized for you.
122 
Let's personalize your content